TVTX vs RARE

For growth investors, Travere Therapeutics, Inc.

(TVTX) is the stronger pick with 110. 5% revenue growth year-over-year, versus 20. 1% for Ultragenyx Pharmaceutical Inc. (RARE). Analysts rate Travere Therapeutics, Inc. (TVTX) a "Buy" — based on 18 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Travere Therapeutics, Inc.

(TVTX) delivered a total return of +113. 2%, compared to -77. 2% for Ultragenyx Pharmaceutical Inc. (RARE). Over 10 years, the gap is even starker: TVTX returned +179. 0% versus RARE's -59. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Ultragenyx Pharmaceutical Inc.

(RARE) is the lower-risk stock at 1. 42β versus Travere Therapeutics, Inc. 's 1. 81β — meaning TVTX is approximately 27% more volatile than RARE relative to the S&P 500.

By revenue growth (latest reported year), Travere Therapeutics, Inc.

(TVTX) is pulling ahead at 110. 5% versus 20. 1% for Ultragenyx Pharmaceutical Inc. (RARE). On earnings-per-share growth, the picture is similar: Travere Therapeutics, Inc. grew EPS 86. 3% year-over-year, compared to 7. 3% for Ultragenyx Pharmaceutical Inc.. Over a 3-year CAGR, TVTX leads at 64. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Travere Therapeutics, Inc.

(TVTX) is the more profitable company, earning -5. 2% net margin versus -85. 4% for Ultragenyx Pharmaceutical Inc. — meaning it keeps -5. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TVTX leads at -12. 8% versus -79. 5% for RARE. At the gross margin level — before operating expenses — TVTX leads at 97. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for RARE: 97.

1% to $51. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Ultragenyx Pharmaceutical Inc.

(RARE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Travere Therapeutics, Inc. (TVTX) carries a higher beta of 1. 81 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (RARE: -59. 4%, TVTX: +179. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.